Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either therapy
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab; (Note: pregnancy testing should be performed within 14 days prior to randomization according to institutional standards for women of childbearing potential)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
Pregnancy or breast-feeding women; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with taselisib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with tremelimumab and MEDI3617
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide or pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ficlatuzumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bavituximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Not pregnant or nursing, with negative serum pregnancy test; pregnant women are excluded from this study; breastfeeding should be discontinued; timeline: within 3 weeks prior to enrollment
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ramucirumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin; these potential risks may also apply to other agents used in this study.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PLX3397 and sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ponatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with natalizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with WDVAX
Pregnant women are excluded from this study; breastfeeding must be discontinued
Persons who are pregnant are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab or nivolumab; a negative serum pregnancy test is required prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BVD523
Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab, gemcitabine, and oxaliplatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with abemaciclib; a negative serum pregnancy test is required for women of childbearing potential prior to study entry
Breastfeeding should be discontinued
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
EXPANDED ACCESS COHORT: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib and LY2874455
Active pregnancy or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gefitinib or osimertinib agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LY3022855; these potential risks may also apply to the other agents used in this study
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding women are also excluded
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Lactating or breastfeeding women are excluded, breastfeeding should be discontinued prior to being treated with AZD1775; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)
Pregnant or breastfeeding women; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine or IMGN853
Patients may not be pregnant or nursing; pregnant women are excluded from this study; a negative pregnancy test must be documented 7 days or less prior to registration; breastfeeding must be discontinued prior to registration for this clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IMA950-poly-ICLC vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemoembolic agent
Breastfeeding should be discontinued if the mother wishes to participate in this study
Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control \r\n* Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GBM6-AD-poly vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant or nursing patients will be excluded from the study; breastfeeding should be discontinued if the mother is treated with sunitinib or everolimus
Patients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexor
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PTX-200; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with carfilzomib/lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Combotox
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pyrimethamine
Pregnant women are excluded from this study because topotecan and temozolomide are class D agents with the potential for teratogenic or abortifacient effects and because the effects of M7824 on the developing human fetus are currently unknown. In addition, because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with topotecan, temozolomide or M7824, breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib, breastfeeding should be discontinued if the mother is treated with olaparib
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100 + SEL-110
Active pregnancy or breast-feeding: pregnant women are excluded from this study because the effects of osimertinib on the development of the fetus are unknown, and there is potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osimertinib, breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M7824
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
COHORT 3: ENDOMETRIAL CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC201
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with clofarabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax
Pregnant and/or breastfeeding women or unable to maintain use of contraception while on study and for 30 days after the last dose of study drug; breastfeeding should be discontinued if the mother is treated with ONC201
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with EGF816 and gefitinib
Women who are breast-feeding or pregnant as evidenced by positive serum or urine pregnancy test performed within 72 hours of first dosing. (Pregnant women are excluded from this study because it is not known whether IACS-010759 has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IACS-010759 breastfeeding should be discontinued if the mother is treated with IACS-010759.)
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Pregnant women are excluded from this study because INCB039110, dabrafenib, and trametinib may have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the mother being treated with the study drugs.
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant women are excluded from this study; in nursing mothers, breastfeeding should be discontinued
Breastfeeding should be discontinued if the mother is treated with nivolumab
Breastfeeding must be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study because meclizine is class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with meclizine, breastfeeding should be discontinued if the mother is treated with meclizine.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with fostamatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with DAC-THU
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with trametinib
Breastfeeding should be discontinued if the mother wishes to participate in this study
Pregnant women, or women who intend to become pregnant during the study, are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD8186; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IORT
Female patients who are breastfeeding; breastfeeding should be discontinued if the mother is treated with Pexa-Vec
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Breastfeeding should be discontinued if the mother is treated with E6 TCR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either of those agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either dabrafenib, trametinib, or the combination of dabrafenib and trametinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lamivudine
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant women are excluded from this study because the agent used in this study has the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or MK-3475 (pembrolizumab)
Pregnant women are excluded from this study; breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled in the trial
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Female participants pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pregnancy or lactation period; note: a negative pregnancy test is required for women of childbearing potential; women who are postmenopausal (age-related amenorrhea >= 12 consecutive months or follicle-stimulating hormone [FSH] > 40 milli international units per milliliter [mIU/ml]), or who had undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing; if necessary to confirm postmenopausal status a FSH level will be included at screening; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with avelumab; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with avelumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1127 (varlilumab) or nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SBRT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184 and nivolumab
Pregnancy and breastfeeding: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus and fosbretabulin
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-2
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cisplatin or radiation on this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with isatuximab
Pregnant women are excluded; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with intraperitoneal interferons
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant and/or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with durvalumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-100
Breastfeeding should be discontinued if the mother is treated with LMB-100; these potential risks may also apply to other agents used in this study
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cesium 131
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101 and/or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IRX5183
Pregnant women are excluded; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the\r\nmother is treated with ramucirumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib and not resumed until at least 2 weeks after the final dose
Pregnancy or breast feeding; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; breastfeeding must be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Breastfeeding should be discontinued if the mother is treated with pomalidomide; these potential risks may also apply to other agents used in this study
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Subject is pregnant or nursing; breastfeeding should be discontinued if the mother is treated with ACY-1215
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded; breastfeeding should be discontinued prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine
Pregnant or nursing females are to be excluded; breastfeeding should be discontinued if the mother is treated with taladegib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemotherapy and/or radiation
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosine
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is being treated on this trial.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued for the duration of active study therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temozolomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with indium In 111 (111In-) and 90Y-basiliximab-DOTA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept
Pregnant women are excluded from this study; breastfeeding should be discontinued while on study; patients who become pregnant while on study will be removed from the study once the pregnancy is confirmed
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs
Pregnancy or breast feeding; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; breastfeeding must be discontinued if the mother is treated with MK-3475
Excluded patient groups:\r\n* Pregnant women are excluded from this study; breastfeeding women will not be included in the study\r\n* Human immunodeficiency virus (HIV)-seropositive patients are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lapatinib of bevacizumab, breastfeeding should be discontinued if the mother is treated on this study
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
A nursing mother unwilling to discontinue breastfeeding; breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiation
Pregnant women are excluded from this study because it is unknown if STA-9090 has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother STA-9090, breastfeeding should be discontinued if the mother is treated with STA-9090; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study. Breastfeeding should be discontinued if the mother is treated with cenersen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CPI-613
Pregnant or planning pregnancy within the next 6 months, or breastfeeding; breastfeeding should be discontinued if the mother is treated with 5-fluorouracil
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant or breastfeeding (Note: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or nursing (lactating) women; NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant women or women who expect to conceive a child are excluded from the study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX970); these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232 through 1 week after receiving the last dose of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Mylotarg
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with navitoclax and vistusertib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from ECP; breastfeeding should be discontinued if the mother is treated with methoxsalen; pregnancy will be evaluated prior to the initiation of ECP
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines
Pregnancy or nursing or unwilling to take adequate birth control during therapy \r\n* NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX-1401 or CDX-301 and poly-ICLC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for eligibility
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 5-FU/capecitabine; pregnancy testing will be completed on all female participants of child-bearing potential by urine analysis
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD6244
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TPI 287
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with HDACI and radiation; women of childbearing age and men sexually active with woman of childbearing age must agree to an acceptable method of birth control (double barrier) while on study
Patient is pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is participating in this study
Pregnancy, nursing, or unwilling to take adequate birth control during therapy\r\n* NOTE: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with INCB024360 and MELITAC 12.1
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin
Breastfeeding should be discontinued if the mother is treated with PF-04449913
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study; women who are breast feeding their infants should discontinue this practice if the mother is treated with ruxolitinib
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinib
Pregnant/nursing women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oxaliplatin or mitomycin C
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-12; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Breastfeeding should be discontinued
Female participants pregnant or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide; these potential risks may also apply to other agents used in this study; lactating females must agree not to breast feed while taking lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AZD1775 and cisplatin; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with proton radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to beginning treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant or lactating women are excluded; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 232
Pregnant and nursing women; breastfeeding should be discontinued if the mother is treated with combination ETBX-011, ETBX-051, ETBX-061
Pregnant women are excluded from this study; breastfeeding should be discontinued while the mother is receiving protocol therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this research protocol
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study)
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pIL-12 EP + pembrolizumab
Pregnant women are excluded; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib; potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8327
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin and gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPI-145
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to starting study treatment
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; breastfeeding should be discontinued if the mother is treated on this study with idelalisib and ofatumumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents and/or radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued upon start of protocol therapy
Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with curcumin
Pregnant or breastfeeding women are excluded from this study; breastfeeding must be discontinued if the mother is treated with sunitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if patient wishes to participate in study
PHASE I: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib; potential risks may also apply to other agents used in this study
PHASE II: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GSK1120212 and GSK2141795
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib and/or fulvestrant
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent, and for 30 days after discontinuation of therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Breast-feeding should be discontinued if a nursing mother is to be treated on clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a class D agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomide
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Pregnant women are excluded; breastfeeding should be discontinued prior to participation of the mother on study
Pregnant women are excluded from this study; breastfeeding must be discontinued while the mother is taking study drug and for at least 28 days after discontinuation of study drug
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AMG 386
Pregnant women are excluded from this study. mFOLFIRINOX is a regimen containing more than one chemotherapy agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with FOLFIRINOX, breastfeeding should be discontinued if the mother is treated with these agents. These potential risks may also apply to other agents used in this study.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX101
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated sorafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on either arm of the trial
Pregnant women are excluded from this study; breastfeeding is not allowed during study treatment
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sonidegib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with eltrombopag
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and eribulin
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to entry onto the study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued at least two weeks prior to the start of PF-00299804 dosing
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with entinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with E7389
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ganetespib; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Lactating or pregnant; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant or nursing; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy\r\n* Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775/belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-1775
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant or breastfeeding women are excluded from this study because tretinoin is a retinoid derivative agent with the potential for teratogenic or abortifacient effects; because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with tretinoin, breastfeeding should be discontinued if the mother is treated with tretinoin; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated in this protocol
Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MPDL3280A
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206 and/or dinaciclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CUDC-907; these potential risks may also apply to other agents used in this study
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral tetrahydrouridine- decitabine [THU-Dec])
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib R-ICE
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MVA-brachyury-TRICOM; these potential risks may also apply to other agents used in this study
Pregnancy or lactation; breastfeeding should be discontinued if the mother is treated with this regimen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-2206
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pioglitazone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study and women who become pregnant while on study must be immediately discontinued; women who are breastfeeding will not be eligible for study participation
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with DMS612
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus or bevacizumab, breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BMN 673 or AT13387
Pregnant women (admittedly, an unlikely event) are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ivabradine
Pregnant women are excluded from this study; breastfeeding should be discontinued by nursing mothers who agree to participate in the study
Female subjects who are pregnant, have a positive serum human chorionic gonadotrophin (hCG), or are lactating and intend to breast feed a child; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NEPA
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naltrexone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Patients who are pregnant or nursing are excluded; breastfeeding should be discontinued if the mother is treated with cytotoxic chemotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with isoquercetin; these potential risks may also apply to other agents used in this study
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with INO-8000
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated\r\nwith simvastatin
Pregnant or lactating women; breastfeeding should be discontinued if the mother is treated with aspirin; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
Pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with the vaccine
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with simvastatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this vaccine
RECIPIENT: Pregnant women and women who are lactating. The risks of CMV?MVA?Triplex to pregnant women are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother. Breastfeeding should be discontinued if the mother is enrolled on this study
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant or breast feeding; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Meriva
Pregnant or lactating women are excluded from this study; breastfeeding must be discontinued for the duration of study participation and for 56 days after the last dose of the study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Women must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with iloprost
Women who are pregnant or breastfeeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pravastatin
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excluded
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with berberine; women are considered to be of child-bearing potential if they are not surgically sterile or under the age 65 and have menstruated within the last two years
Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naproxen
Participants who are pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Polyphenon E
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965
Pregnant or lactating women; breastfeeding should be discontinued if the mother is treated with aspirin; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with 9cUAB30
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 64Cu-M5A
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; women who are breastfeeding are also excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study
Pregnant women are excluded from this study because chemoradiotherapy has the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to the use of ferumoxytol as a contrast agent in the mother, breastfeeding should be discontinued if the mother receives ferumoxytol while nursing; men who are sexually active and not willing/able to use medically acceptable forms of contraception are also excluded from this study
Pregnant women are excluded from this study; breastfeeding mothers are also excluded from this study
Women who are pregnant or may become pregnant, as well as those women who are breastfeeding, will be excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother has been exposed to L-[methyl-11C]methionine; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SL-401 and azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with APR-246
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2014
Pregnant or lactating women; breastfeeding should be discontinued if the mother receives 18F-FdCyd
Pregnant or lactating women: pregnant women are excluded from this study; breastfeeding should be discontinued for at least one day if the mother receives 68Ga-DOTATATE
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with ALA
Pregnant or nursing women or men/women of child-bearing potential who are unwilling to employ adequate contraception\r\n* Pregnant and nursing women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled on the study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LB100
Pregnant women are excluded. Breastfeeding should be discontinued if the mother is treated with LUM015.
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab
Pregnant women are excluded from this study; breastfeeding must be discontinued.
